Lee Ainslie Akebia Therapeutics, Inc. Transaction History

Maverick Capital LTD

  • $4.82 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022
SELL
$2.26 - $3.34 $239,144 - $353,425
-105,816 Closed
0 $0
Q3 2021

Nov 15, 2021
BUY
$2.35 - $3.88 $248,667 - $410,566
105,816 New
105,816 $305,000
Q2 2021

Aug 16, 2021
SELL
$2.83 - $4.2 $397,196 - $589,478
-140,352 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$2.92 - $5.06 $409,827 - $710,181
140,352 New
140,352 $475,000

Others Institutions Holding AKBA

# of Institutions
120
Shares Held
54.8M
Call Options Held
291K
Put Options Held
179K
View Full List

About Akebia Therapeutics, Inc.

AKBA Quotes by TradingView
  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $324M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track Lee Ainslie's Portfolio

Track Lee Ainslie Portfolio

Follow Lee Ainslie (Maverick Capital LTD) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email